Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Prostatic cancer vaccine

a prostate cancer and vaccine technology, applied in the field of prostate cancer vaccine, can solve the problems of increasing life expectancy, slow vaccine development, and refractory prostate cancer to treatment, and achieve the effect of elimination of the prostate gland

Inactive Publication Date: 2006-02-02
SPITLER LYNN E +1
View PDF14 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0010] While the prior art suggests the use of antigens uniquely associated with tumor tissue as components of antitumor vaccines, there appears to be no suggestion to use antigens which are uniquely represented on host tissue for the tumor. Since the prostate is not an essential organ, elimination of the prostate gla

Problems solved by technology

Cancer is a leading cause of death in all industrialized nations, where life expectancy continues to increase.
Prostate cancer continues to be refractory to treatment despite many years of efforts to improve therapy.
Vaccine development has been slow and no vaccine approved by the FDA for marketing currently exists for any form of cancer.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0013] The invention utilizes compositions which contain, as active ingredient, at least one antigen which is over-represented on prostate tissue or an immunologically effective portion thereof or a representative thereof. By “over-represented” is meant that the concentration of this antigen in prostate is sufficiently higher than its concentration in any other tissue such that the prostate can effectively be targeted by the immune response raised against this antigen with relative sparing of other organs or tissues. Sparing can be measured by overall clinical toxicity to the subject. Toxicity to the subject is generally grade 3 or less, preferably grade 2 or less most preferably grade 1 or grade 0. The approach does not lose value with regard to metastatic prostate cancer, since the antigens over-represented in the prostate gland are also carried by the metastatic cells.

[0014] By an “immunologically effective portion thereof” is meant that portion of an antigen, taken alone, which...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Vaccines capable of eliciting an immune antitumor response for prostate tumors are disclosed. The active ingredient in such vaccines is selected from the group consisting of at least one antigen over-represented in the prostate gland or an immunologically effective portion thereof; an expression system capable of generating in situ said antigen or portion; a naked DNA encoding such antigen and portion; and an anti-idiotypic antibody or fragment thereof which mimics said antigen or portion.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of U.S. application Ser. No. 09 / 300,978, filed Apr. 28, 1999, which is a continuation of U.S. application Ser. No. 08 / 288,057, filed Aug. 10, 1994, now U.S. Pat. No. 5,925,362, which is a continuation-in-part of U.S. application Ser. No. 08 / 105,444, filed Aug. 11, 1993. The disclosures of the above-described applications are incorporated herein by reference in their entirety.TECHNICAL FIELD [0002] The present invention is related to the field of the prevention and treatment of prostate cancer. More specifically, the invention concerns the use of (1) prostate associated antigen(s), (2) expression systems for prostate associated antigen(s) which are peptides or proteins or (3) anti idiotypic antibodies bearing the internal image of the antigen(s) formulated as vaccines to produce an immune response to prevent or treat prostate cancer. BACKGROUND ART [0003] Cancer is the second leading cause of death in t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395A61K39/00A61P13/08A61P35/00A61P37/04C07K14/475C07K16/42C12N15/09C12P21/02
CPCA61K39/00Y10S424/812C07K16/4241A61K39/0011A61P13/08A61P35/00A61P37/04
Inventor SPITLER, LYNN E.MAIDA, ANTHONY E. III
Owner SPITLER LYNN E
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com